000285478 001__ 285478
000285478 005__ 20260309095117.0
000285478 0247_ $$2doi$$a10.1002/alz.71195
000285478 0247_ $$2pmid$$apmid:41736364
000285478 0247_ $$2pmc$$apmc:PMC12932912
000285478 0247_ $$2ISSN$$a1552-5260
000285478 0247_ $$2ISSN$$a1552-5279
000285478 037__ $$aDZNE-2026-00255
000285478 041__ $$aEnglish
000285478 082__ $$a610
000285478 1001_ $$0P:(DE-2719)9001652$$aGnörich, Johannes$$b0$$eFirst author$$udzne
000285478 245__ $$aLongitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET.
000285478 260__ $$aHoboken, NJ$$bWiley$$c2026
000285478 3367_ $$2DRIVER$$aarticle
000285478 3367_ $$2DataCite$$aOutput Types/Journal article
000285478 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1773046068_14565
000285478 3367_ $$2BibTeX$$aARTICLE
000285478 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285478 3367_ $$00$$2EndNote$$aJournal Article
000285478 520__ $$aProgressive supranuclear palsy (PSP), a 4-repeat tauopathy, can be visualized using [18F]PI-2620 tau positron emission tomography (PET). However, the value of sequential [18F]PI-2620 imaging for tracking tau accumulation during the disease course has not yet been investigated.Twenty-three PSP patients underwent two [18F]PI-2620 PET scans (interval: 21.4 ± 4.3 months) and were compared to cross-sectional data from 25 healthy controls. Regional volume of distribution ratio values were analyzed for longitudinal tau changes, clinical correlations, and network-based propagation. Post mortem analyses examined neuronal density and AT8 tau pathology.Subcortical tau PET signals increased, strongest in the globus pallidus internus (P < 0.0001). Patients with low baseline tau showed the largest increases. Despite clinical worsening (Progressive Supranuclear Palsy Rating Scale +48%), tau PET change did not correlate with symptom progression. Tau accumulation followed functional connectivity (R = 0.34, P < 0.0001). Post mortem data linked elevated tau PET to higher AT8 burden despite neuronal loss.[18F]PI-2620 PET enables monitoring of tau progression in PSP, indicating network-based tau propagation with saturation in advanced stages.
000285478 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000285478 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000285478 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x2
000285478 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285478 650_7 $$2Other$$a4‐repeat tauopathies
000285478 650_7 $$2Other$$adisease monitoring
000285478 650_7 $$2Other$$aprogressive supranuclear palsy
000285478 650_7 $$2Other$$atau positron emission tomography
000285478 650_7 $$2Other$$atau spreading
000285478 650_7 $$2NLM Chemicals$$atau Proteins
000285478 650_7 $$2NLM Chemicals$$aFluorine Radioisotopes
000285478 650_7 $$2NLM Chemicals$$aPI-2620
000285478 650_7 $$2NLM Chemicals$$aPyridines
000285478 650_2 $$2MeSH$$aHumans
000285478 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnostic imaging
000285478 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: metabolism
000285478 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: pathology
000285478 650_2 $$2MeSH$$aPositron-Emission Tomography
000285478 650_2 $$2MeSH$$atau Proteins: metabolism
000285478 650_2 $$2MeSH$$aMale
000285478 650_2 $$2MeSH$$aFemale
000285478 650_2 $$2MeSH$$aAged
000285478 650_2 $$2MeSH$$aLongitudinal Studies
000285478 650_2 $$2MeSH$$aMiddle Aged
000285478 650_2 $$2MeSH$$aDisease Progression
000285478 650_2 $$2MeSH$$aBrain: diagnostic imaging
000285478 650_2 $$2MeSH$$aBrain: metabolism
000285478 650_2 $$2MeSH$$aBrain: pathology
000285478 650_2 $$2MeSH$$aCross-Sectional Studies
000285478 650_2 $$2MeSH$$aFluorine Radioisotopes
000285478 650_2 $$2MeSH$$aPyridines
000285478 7001_ $$aKusche-Palenga, Julia$$b1
000285478 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b2$$udzne
000285478 7001_ $$0P:(DE-2719)9002868$$aNeubauer, Antonia$$b3$$udzne
000285478 7001_ $$aFrontzkowski, Lukas$$b4
000285478 7001_ $$0P:(DE-2719)9002626$$aJäck, Alexander$$b5$$udzne
000285478 7001_ $$aKling, Agnes$$b6
000285478 7001_ $$aBauer, Theresa$$b7
000285478 7001_ $$aEyob, Hannah$$b8
000285478 7001_ $$aProbst, Katharina$$b9
000285478 7001_ $$aRoemer-Cassiano, Sebastian N$$b10
000285478 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander M$$b11$$udzne
000285478 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b12$$udzne
000285478 7001_ $$0P:(DE-2719)9003208$$aMarth, Lena$$b13$$udzne
000285478 7001_ $$aZaganjori, Mirlind$$b14
000285478 7001_ $$0P:(DE-2719)9003372$$aHopfner, Franziska$$b15$$udzne
000285478 7001_ $$aZwergal, Andreas$$b16
000285478 7001_ $$aHäckert, Jan$$b17
000285478 7001_ $$aRullmann, Michael$$b18
000285478 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b19$$udzne
000285478 7001_ $$aBarthel, Henryk$$b20
000285478 7001_ $$0P:(DE-2719)9003671$$aStöcklein, Sophia$$b21$$udzne
000285478 7001_ $$aWerner, Rudolf A$$b22
000285478 7001_ $$0P:(DE-2719)2811642$$aSimons, Mikael$$b23$$udzne
000285478 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b24$$udzne
000285478 7001_ $$0P:(DE-2719)2810441$$aHerms, Jochen$$b25$$udzne
000285478 7001_ $$aFranzmeier, Nicolai$$b26
000285478 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b27$$udzne
000285478 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b28$$eLast author$$udzne
000285478 7001_ $$aTauopathies, German Imaging Initiative for$$b29$$eCollaboration Author
000285478 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.71195$$gVol. 22, no. 2, p. e71195$$n2$$pe71195$$tAlzheimer's and dementia$$v22$$x1552-5260$$y2026
000285478 8564_ $$uhttps://pub.dzne.de/record/285478/files/DZNE-2026-00255.pdf$$yRestricted
000285478 8564_ $$uhttps://pub.dzne.de/record/285478/files/DZNE-2026-00255.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001652$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002868$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002626$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002620$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003208$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000285478 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003372$$aExternal Institute$$b15$$kExtern
000285478 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b19$$kExtern
000285478 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003671$$aExternal Institute$$b21$$kExtern
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811642$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b23$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810441$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000285478 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b28$$kDZNE
000285478 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000285478 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000285478 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x2
000285478 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-11$$wger
000285478 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285478 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285478 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000285478 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000285478 9201_ $$0I:(DE-2719)1110001$$kAG Herms$$lTranslational Brain Research$$x2
000285478 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x3
000285478 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x4
000285478 980__ $$ajournal
000285478 980__ $$aEDITORS
000285478 980__ $$aVDBINPRINT
000285478 980__ $$aI:(DE-2719)1110007
000285478 980__ $$aI:(DE-2719)1111015
000285478 980__ $$aI:(DE-2719)1110001
000285478 980__ $$aI:(DE-2719)1110008
000285478 980__ $$aI:(DE-2719)1111016
000285478 980__ $$aUNRESTRICTED